Navigation Links
aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Date:8/14/2013

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative disease therapeutics enterprise, announced today the expansion of the company's executive leadership team. Ms. Kelly Blackburn joins aTyr as vice president, Clinical Affairs. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases. aTyr is advancing a therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immunology.

(Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO)

"At this key point in aTyr's evolution, the expansion of our executive leadership will help advance our first therapeutic program into the clinic in rare diseases," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. "Ms. Blackburn has more than 20 years of experience in managing and leading clinical programs, including the development of innovative molecules for rare diseases.  We look forward to Kelly's leadership as we work to rapidly translate our leading research in new Physiocrine biology into therapeutics for patients with grave immune diseases."

Ms. Blackburn was formerly the vice president, Clinical Development Operations at Vertex Pharmaceuticals where she was responsible for the operational plans and strategy for the full product portfolio including two transformational programs, KalydecoTM and Incivek®. Prior to Vertex, she was director, Clinical and Safety Operations at Millenium Pharmaceuticals, where she was operationally responsible for the lead product, VELCADE®.  Previous to that, she held several clinical operations roles of increasing responsibility at Vertex, Genetics Institute and Bayer Corporate. Ms. Blackburn received her B.S. in biochemistry from University of New Hampshire, MHA from Quinnipiac College and M.Ed. from Cambridge College.

About Physiocrines

Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. Physiocrines are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation. As potent endogenous modulators of inflammation, Physiocrines offer the opportunity for modulating biological pathways through new naturally occurring mechanisms, many of which have multiple therapeutic advantages, including improved selectivity, efficacy and reduced side effect profiles compared to many existing anti-inflammatory therapeutics.

About aTyr Pharma

aTyr Pharma has developed an extensive pipeline of future therapeutic products based on Physiocrine biology. aTyr has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr's key programs are currently focused on rare immunomodulation disorders in the areas of inflammation and immunity. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
4. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
5. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
6. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. PipelineRx Announces Telepharmacy Contract with GNYHA Services
8. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
9. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
10. Valeant Pharmaceuticals Announces Continuance
11. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):